Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation

Brain Research

Volumn 812, Issue 1-2, 1998, Pages 65-75

  Duncan, Gary E ^a   Leipzig, Jeremy N ^a   Mailman, Richard B ^a   Lieberman, Jeffery A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Clozapine; Haloperidol; Hippocampus; Ketamine; Limbic system; NMDA; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN METABOLISM; DRUG EFFECT; DRUG MECHANISM; GLUCOSE TRANSPORT; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; LIMBIC SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; BRAIN; CLOZAPINE; DEOXYGLUCOSE; EXCITATORY AMINO ACID ANTAGONISTS; HALOPERIDOL; KETAMINE; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032561707     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00926-3     Document Type: Article

References (70)

1. Angrist B., Gerson S. The phenomenology of experimentally induced amphetamine psychosis-preliminary observations. Biol. Psychiatry. 2:1970;95-107.
2. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. 283:1997;226-234.
3. Bakker C.B., Amini F.B. Observations on the psychotomimetic effects of sernyl. Compr. Psychiatry. 2:1961;269-280.
4. Bakshi V.P., Swerdlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271:1994;787-794.
5. Banerjee S.P., Zuck L.G., Yablonsky-Alter E., Lidsky T.I. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. NeuroReport. 6:1995;2500-2504.
6. Bristow L.J., Hutson P.H., Thorn L., Tricklebank M.D. The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br. J. Pharmacol. 108:1993;1156-1163.
7. Bustos G., Abarca J., Forrey M.I., Gysling K., Bradbery C.W., Roth R.H. Regulation of excitatory amino acid release by N-methyl-D-aspartate receptors in rat striatum: in vivo microdialysis studies. Brain Res. 585:1992;105-115.
8. Bubser M., Tzschentke T., Hauber W. Behavioral and neurochemical interactions of the AMPA antagonist GYKI 52466 and the noncompetitive NMDA antagonist dizocilpine in rats. J. Neural. Transm. Gen. Sect. 101:1995;115-126.
9. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;72-276.
10. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharm. 120:1995;67-74.
11. Corssen G., Domino E.F. Dissociative anesthesia: further pharmacologic studies and first clinical experience with phencyclidine derivative Cl-581. Anesth. Analg. 45:1966;29-40.
12. Davies B.M., Beech H.R. The effect of 1-arylcyclohexylamine (sernyl) on twelve normal volunteers. J. Ment. Sci. 106:1960;912-924.
13. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry. 148:1991;1474-1486.
14. Deutsch S.I., Mastropaolo J., Schwartx B.L., Rosse R., Morihisa J.M. A glutamate hypothesis of schizophrenia. Clin. Neuropharmacol. 12:1989;1-13.
15. G.E. Duncan, High resolution autoradiographic imaging of brain activity patterns with 2-deoxyglucose: regional topographic and cellular analysis, in: F. Gonzalez-Lima, Th. Finkenstadt, H. Scheich (Eds.), Advances in metabolic mapping techniques for brain imaging of behavioral and learning functions, NATO Advanced Science Institute Series, Vol. 68, 1992, pp. 152-173.
16. Duncan G.E., Stumpf W.E. Brain activity patterns: Assessment by high resolution autoradiographic imaging of radiolabeled 2-deoxyglucose and glucose uptake. Prog. Neurobiol. 37:1991;365-382.
17. G.E. Duncan, W.E. Stumpf, High resolution autoradiographic imaging of brain activity patterns with radiolabeled 2-deoxyglucose, in: P.M. Conn (Ed.), Methods in Neurosciences, Vol. 3, Academic Press, New York, 1990, pp. 50-64.
18. Duncan G.E., Johnson K.B., Breese G.R. Topographic patterns of brain activity in response to swim stress: Assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity. J. Neurosci. 13:1993;3932-3943.
19. Duncan G.E., Knapp D.J., Johnson K.B., Breese G.R. Functional classification of antidepressants based upon antagonism of swim stress-induced Fos-like immunoreactivity. J. Pharmacol. Exp. Ther. 277:1996;1076-1089.
20. Duncan G.E., Moy S.S., Knapp D.J., Mueller R.A., Breese G.R. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res. 787:1998;181-190.
21. Farber N.B., Price M.T., Labruyere J., Nemnich J., St. Peter H., Wozniak D.F., Olney J.W. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol. Psychiatry. 34:1993;119-121.
22. Farber N.B., Foster J., Duhan N.L., Olney J.W. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr. Res. 21:1996;33-37.
23. Fix A.S., Horn J.W., Wightman K.A., Johnson C.A., Long G.G., Storts R.W., Farber N., Wozniak D.F., Olney J.W. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp. Neurol. 123:1993;204-215.
24. Freeman A.S., Bunney B.S. The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur. J. Pharmacol. 104:1984;287-293.
25. French E.D., Ceci A. Non-competitive N-methyl-D-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons. Neurosci. Lett. 119:1990;159-162.
26. Griffith J., Cavanaugh J., Held N., Oates J. D-amphetamine: evaluation of psychotomimetic properties in man. Arch. Gen. Psychiatry. 26:1972;97-100.
27. Goldman-Rakic P.S., Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. 23:1997;437-458.
28. Hauber W. Clozapine improves dizocilpine-induced delayed alternation impairments in rats. J. Neural. Transm. Gen. Sect. 94:1993;223-233.
29. Hauber W., Andersen R. The non-NMA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn-Schmiedeberg's Arch. Pharmacol. 348:1993;486-490.
30. Hoffman D.C. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Trans. 89:1992;1-10.
31. Hondo H., Yonezawa Y., Nakahara T., Nakamura K., Hirano M., Uchimaura H., Tashiro N. Effect of phencyclidine on dopamine release in the rat prefrontal cortex, an in vivo microdialysis study. Brain Res. 633:1994;337-342.
32. Horvath Z.C., Czopf J., Buzsaki G. MK-801-induced neuronal damage in rats. Brain Res. 753:1997;181-195.
33. Imperato A., Scrocco M.G., Bacchi S., Angelucci L. NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur. J. Pharmacol. 187:1990;555-556.
34. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
35. Keefe K.A., Zigmond M.J., Abercrombie E.D. In vivo regulation of extracellular dopamine in the neostriatum: influence of impulse activity and local excitatory amino acid release. J. Neural. Transm. 91:1993;223-240.
36. Krystal J.H., Karper L., Pseibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of noncompetitive NMDA antagonist, ketamine, in humans. Arch. Gen. Psychiatry. 51:1994;199-214.
37. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
38. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport. 6:1995;869-872.
39. Lieberman J.A., Kane J.M., Alvir J.A.J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 91:1987;415-433.
40. Liu J., Moghaddam B. Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. J. Pharmacol. Exp. Ther. 274:1995;1209-1215.
41. Luby E.D., Cohen B.D., Rosenbaum G., Gottilieb J.S., Kelley R. Study of a new schizophrenomimetic drug - sernyl. Arch. Neurol. Psych. 81:1959;363-369.
42. Malhortra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14:1996;301-307.
43. Malhortra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol. Psychiatry. 42:1997;664-668.
44. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150.
45. Martin P., Waters N., Carlsson A., Carlsson M.L. The apparent antipsychotic action of the 5-HT2a receptor antagonist MDL-100907 in a mouse model of schizophrenia is counteracted by ritanserin. J. Neural Transm. 104:1997;561-564.
46. McCown T.J., Duncan G.E., Breese G.R. Neuroanatomical characterization of inferior collicular seizure genesis: 2-deoxyglucose and stimulation mapping. Brain Res. 567:1991;25-32.
47. McCown T.J., Duncan G.E., Johnson K.B., Breese G.R. Metabolic and functional mapping of the neural network subserving inferior collicular seizure generalization. Brain Res. 701:1995;117-128.
48. Meltzer H.Y. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br. J. Psychiatry. 168:1996;23-31. suppl. 29.
49. i values. J. Pharm. Exp. Ther. 251:1989;238-246.
50. Meltzer H.Y., Stahl S.M. The dopamine hypothesis of schizophrenia: A review. Schizophr. Bull. 2:1976;19-76.
51. Moghaddam B., Adams B., Verman A., Daly D. Activation of glutamaterigic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17:1997;2921-2927.
52. Nakki R., Nickolenko J., Chang J., Sagar S.M., Sharp F.R. Haloperidol prevents ketamine and phencyclidine induced hsp70 protein expression but not microglial activation. Exp. Neurol. 137:1996;234-241.
53. Norman R.M., Malla A.K., Morrison-Stewart S.L., Helmes E., Williamson P.C., Thomas J., Cortese L. Neuropsychological correlates of syndromes in schizophrenia. Br. J. Psychiatry. 170:1997;134-139.
54. 2 receptor occupancy studies and clinical response. Br. J. Psychiatry. 168:1996;40-44. suppl 29.
55. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: Mechanism and protection. Science. 54:1991;1515-1518.
56. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
57. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, 1997.
58. Rao T.S., Kim H.S., Lehman J., Martin L.L., Wood P. Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo. Life Sci. 45:1989;1067-1072.
59. 2A receptor blocade. J. Pharm. Exp. Ther. 277:1996;1541-1549.
60. Seeman P., Corbett R., Van Tol H.H. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology. 16:1997;93-110.
61. Sharp J.W., Petersen D.L., Langford M.T. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp 70 heat shock gene in the rat cingulate and retrosplenial cortex. Brain Res. 687:1995;114-124.
62. Sharp F.R., Butman M., Wang S., Kiostanaho J., Grahm S., Burger P., Sagar S.M., Longo F.M. Haloperidol and rimcazole prevent induction of HSP72 protein and hsp70 mRNA in neurons injured by phencyclidine and MK-801. J. Neurosci. Res. 33:1992;605-616.
63. Snyder S.H., Banerjee S.P., Yamamura H.I., Greenberg D. Drugs, neurotransmitters, and schizophrenia. Science. 184:1974;1243-1253.
64. Steinfels G.F., Tam S.W., Cook L. Electrophysiological effects of selective σ-receptor agonists, antagonists and the selective phencyclidine receptor agonist, MK-801 on midbrain dopamine neurons. Neuropharmacology. 2:1989;201-208.
65. Tiedtke P.I., Bischoff C., Schmidt W.J. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J. Neural. Transm. Gen. Sect. 81:1990;173-182.
66. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16:1996;373-379.
67. Wang R.Y., Liang X. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology. 19:1998;74-85.
68. Wedzony K., Klimek V., Golembiowska K. MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Res. 622:1993;325-329.
69. Willins D.L., Narayanan S., Wallace L.J., Uretsky N.J. The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801. Pharmacol. Biochem. Behav. 46:1993;881-887.
70. Wolf M.E., White F.J., Hu X.T. Behavioral sensitization to MK-801 (dizocilpine): neurochemical and electrophysiological correlates in the mesoaccumbens dopamine system. Behav. Pharmacol. 4:1993;429-442.